Amedisys, Inc. (NASDAQ:AMED) Short Interest Up 24.0% in May

Amedisys, Inc. (NASDAQ:AMEDGet Rating) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 1,500,000 shares, a growth of 24.0% from the May 15th total of 1,210,000 shares. Approximately 4.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 317,200 shares, the days-to-cover ratio is presently 4.7 days.

AMED has been the subject of several recent analyst reports. Oppenheimer reissued an “outperform” rating and set a $200.00 price objective on shares of Amedisys in a report on Friday, April 29th. Credit Suisse Group dropped their target price on Amedisys from $200.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, February 25th. UBS Group upgraded Amedisys from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $152.00 to $168.00 in a research report on Tuesday, March 1st. Raymond James lowered their price objective on Amedisys from $200.00 to $180.00 in a research report on Friday, April 29th. Finally, Truist Financial lowered their price objective on Amedisys from $210.00 to $200.00 and set a “buy” rating for the company in a research report on Friday, February 25th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Amedisys has a consensus rating of “Buy” and an average target price of $189.80.

Shares of AMED opened at $115.64 on Friday. The business’s 50 day moving average is $126.82 and its 200 day moving average is $143.20. The company has a market capitalization of $3.77 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 2.35 and a beta of 0.89. Amedisys has a 12-month low of $109.30 and a 12-month high of $276.21. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.42.

Amedisys (NASDAQ:AMEDGet Rating) last released its quarterly earnings results on Wednesday, April 27th. The health services provider reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.12. The business had revenue of $545.26 million during the quarter, compared to analysts’ expectations of $557.81 million. Amedisys had a return on equity of 19.37% and a net margin of 8.59%. During the same quarter last year, the business posted $1.54 EPS. Equities research analysts predict that Amedisys will post 5.29 earnings per share for the current year.

In other Amedisys news, insider David L. Kemmerly sold 2,500 shares of Amedisys stock in a transaction dated Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the completion of the transaction, the insider now owns 16,336 shares of the company’s stock, valued at approximately $2,896,536.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in Amedisys by 3.7% during the 1st quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider’s stock valued at $671,378,000 after purchasing an additional 138,484 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Amedisys by 3.5% in the 1st quarter. Wellington Management Group LLP now owns 1,875,274 shares of the health services provider’s stock worth $323,092,000 after acquiring an additional 62,863 shares in the last quarter. Riverbridge Partners LLC raised its position in shares of Amedisys by 6.6% in the 1st quarter. Riverbridge Partners LLC now owns 1,693,656 shares of the health services provider’s stock worth $291,800,000 after acquiring an additional 104,906 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Amedisys by 23.5% in the 1st quarter. JPMorgan Chase & Co. now owns 1,384,041 shares of the health services provider’s stock worth $238,457,000 after acquiring an additional 263,275 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Amedisys by 67.7% in the 1st quarter. Mackenzie Financial Corp now owns 956,780 shares of the health services provider’s stock worth $164,844,000 after acquiring an additional 386,411 shares in the last quarter. 90.47% of the stock is owned by institutional investors and hedge funds.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.